Susie Cheng

Partner @Leason Ellis Llp

Susie focuses on all aspects of global strategic patent protection, licensing of inventions and monetization of intellectual property. She also provides advice regarding intellectual property disputes and litigation. Her clients include academic institutions, private equity firms, venture capital firms, individuals, start-ups, privately owned business, mid-cap, and multinational companies who operate in a wide range of technologies including chemicals, biologics (such as vaccines, antisense, proteins, antibodies, stem cells, and growth factors), pharmaceuticals (such as therapeutics for the treatment of cancer, immune disease, rheumatoid arthritis, metabolic disease, lysosomal storage disease, cardiovascular disease, ocular disease, diabetes, and pain), diagnostics, biofuels, nanotechnology, medical devices, cosmetics and personal health products. She provides advice on patent strategies during all stages of drug development including pre-clinical and clinical activities, paragraph IV certifications, and preparation of notice letters. Her services include inventorship investigation, conducting freedom-to-operate, patentability, non-infringement, and validity opinions. Susie advises private equity and venture capital firms on due diligence investigation of target companies\' patent portfolios, products, and involvement in legal proceedings, for investment, licensing, and acquisition opportunities. She also advises on license agreement, research agreement, non-disclosure agreement, stock-purchase agreement, and assignment agreement. For clients doing business in Asia and for clients from Asia, her fluency in Cantonese and Mandarin Chinese makes her a highly effective advocate on their behalf. She is also a regular columnist for the Medicine Economic News, which is affiliated with the Chinese State Food and Drug Administration and the China Intellectual Property News published by SIPO.